CDK9 and plasma cell myeloma: Pembrolizumab in combination with dinaciclib (cyclin dependent kinase 9, CDK9 inhibitor) in patients with R/R CLL, DLBCL and multiple myeloma (MM) showed a ORR of 20-30% in patients with CLL and DLBCL whereas 0% in patients with myeloma (59).